Lessons from the HEALEY adaptive platform trial in amyotrophic lateral sclerosis

on behalf of the HEALEY ALS Platform Trial Study Group

doi:10.1038/s43587-024-00740-x

Lessons from the HEALEY adaptive platform trial in amyotrophic lateral sclerosis

on behalf of the HEALEY ALS Platform Trial Study Group

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

Platform trials present potential advantages over stand-alone clinical trials. Here, we describe the operational framework of the HEALEY Amyotrophic Lateral Sclerosis Platform Trial, which enables an adaptable operational infrastructure, concurrent enrolment into four distinct regimens and an accelerated start-up time for a new regimen added after initial trial launch.

Original language	English (US)
Pages (from-to)	1512-1515
Number of pages	4
Journal	Nature Aging
Volume	4
Issue number	11
DOIs	https://doi.org/10.1038/s43587-024-00740-x
State	Published - Nov 2024

All Science Journal Classification (ASJC) codes

Neuroscience (miscellaneous)
Aging
Geriatrics and Gerontology

Access to Document

10.1038/s43587-024-00740-x

Cite this

@article{ef511c71f7da405797b7e96ec2e5ded6,

title = "Lessons from the HEALEY adaptive platform trial in amyotrophic lateral sclerosis",

abstract = "Platform trials present potential advantages over stand-alone clinical trials. Here, we describe the operational framework of the HEALEY Amyotrophic Lateral Sclerosis Platform Trial, which enables an adaptable operational infrastructure, concurrent enrolment into four distinct regimens and an accelerated start-up time for a new regimen added after initial trial launch.",

author = "\{on behalf of the HEALEY ALS Platform Trial Study Group\} and Sabrina Paganoni and Brittney Harkey and Elisa Giacomelli and Merit Cudkowicz and Xiaowei Su",

note = "Publisher Copyright: {\textcopyright} Springer Nature America, Inc. 2024.",

year = "2024",

month = nov,

doi = "10.1038/s43587-024-00740-x",

language = "English (US)",

volume = "4",

pages = "1512--1515",

journal = "Nature Aging",

issn = "2662-8465",

publisher = "Springer",

number = "11",

}

TY - JOUR

T1 - Lessons from the HEALEY adaptive platform trial in amyotrophic lateral sclerosis

AU - on behalf of the HEALEY ALS Platform Trial Study Group

AU - Paganoni, Sabrina

AU - Harkey, Brittney

AU - Giacomelli, Elisa

AU - Cudkowicz, Merit

AU - Su, Xiaowei

N1 - Publisher Copyright: © Springer Nature America, Inc. 2024.

PY - 2024/11

Y1 - 2024/11

N2 - Platform trials present potential advantages over stand-alone clinical trials. Here, we describe the operational framework of the HEALEY Amyotrophic Lateral Sclerosis Platform Trial, which enables an adaptable operational infrastructure, concurrent enrolment into four distinct regimens and an accelerated start-up time for a new regimen added after initial trial launch.

AB - Platform trials present potential advantages over stand-alone clinical trials. Here, we describe the operational framework of the HEALEY Amyotrophic Lateral Sclerosis Platform Trial, which enables an adaptable operational infrastructure, concurrent enrolment into four distinct regimens and an accelerated start-up time for a new regimen added after initial trial launch.

UR - https://www.scopus.com/pages/publications/85208121146

UR - https://www.scopus.com/inward/citedby.url?scp=85208121146&partnerID=8YFLogxK

U2 - 10.1038/s43587-024-00740-x

DO - 10.1038/s43587-024-00740-x

M3 - Comment/debate

C2 - 39487328

AN - SCOPUS:85208121146

SN - 2662-8465

VL - 4

SP - 1512

EP - 1515

JO - Nature Aging

JF - Nature Aging

IS - 11

ER -

Lessons from the HEALEY adaptive platform trial in amyotrophic lateral sclerosis

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this